NCT00555100 - Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2007

Primary Completion Date

December 1, 2010

Study Completion Date

December 1, 2010

Conditions

Multiple Myeloma

Interventions

DRUG

lenalidomide

10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.

DRUG

dexamethasone

40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.

Trial Locations (5)

Nagoya City University Hospital, Nagoya

National Hospital Organization Nagoya Medical Center, Nagoya

Jichi Medical University Hospital, Shimotsuke

Niigata Cancer Center Hospital, Niigata

Keio University Hospital, Tokyo